Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 227

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 227
---
.(1)       |     |     | 42 |     | Director                                                  |
| Joshua Resnick, M.D., M.B.A.    |     |     | 50 |     | Director                                                  |
| Marcella Kuhlman Ruddy, M.D.(3) |     |     | 62 |     | Director                                                  |
| Laurie Stelzer, M.B.A.(1)(2)    |     |     | 57 |     | Director                                                  |
| Peter A. Thompson, M.D.(3)      |     |     | 65 |     | Director                                                  |
| Joanne Louise Viney, Ph.D.(1)   |     |     | 59 |     | Director                                                  |

| (1) | Member of the compensation committee. |

| (2) | Member of the audit committee. |

| (3) | Member of the nominating and corporate governance committee. |

Executive Officers Michael Cloonan, M.B.A. ,has served as our President, Chief Executive Officer and a member of our board of directors since May 2021. Previously, Mr. Cloonan served as the Chief Operating Officer of Sage Therapeutics, Inc. (NASDAQ: SAGE) (“Sage”) from May 2020 to May 2021, and as the chief business officer of Sage from April 2017 to May 2020. Prior to joining Sage, Mr. Cloonan served in various leadership positions at Biogen, Inc. (NASDAQ: BIIB) (“Biogen”) in various business and commercial roles in his fourteen years at Biogen. His most recent role at Biogen was as senior vice president, U.S. Commercial, where he was the general manager of the multi-billion dollar MS, hemophilia and SMA franchises. Mr. Cloonan has also served on the board of directors of bluebird bio, Inc. (NASDAQ: BLUE) since June 2024. Mr. Cloonan earned a B.A. in economics and accounting from the College of the Holy Cross and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia. We believe Mr. Cloonan’s extensive leadership experience in the biotechnology industry and experience as a public company board member provides him with the appropriate set of skills to serve as a member of our board of directors. Charlotte McKee, M.D., has served as our Chief Medical Officer since June 2021. Previously, Dr. McKee served as vice